Home General Message Hepatitis Industry News Preclinical Trials Viral Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program

Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program

Posted on Tuesday, 2 March 2010 by Health
No Comment BOOKMARK
WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.

Read the full article at Health

Share this Post:
Digg Google Bookmarks reddit Mixx StumbleUpon Technorati Yahoo! Buzz DesignFloat Delicious BlinkList Furl
Tagged with:

No Responses to “Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program”

Leave a Reply:

Name (required):
Mail (will not be published) (required):
Website:
Comment (required):
XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Get Adobe Flash playerPlugin by wpburn.com wordpress themes